Stock Ratings / Health Care / AMIX / earnings

XAIR (42) CODX (37) ICCM (46) NVNO (50) ⌘ Pro Terminal →

Autonomix Medical Inc. (AMIX) Next Earnings Date & Expected ±12.5% Move

Q: Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Autonomix Medical Inc. (NASDAQ: AMIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.04 (-5.12% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AMIX ranks #768 in composite RQD confidence.

Q: How does AMIX compare to XAIR and CODX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AMIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XAIR (Beyond Air Inc.) holds a D- grade (42/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M) and CODX (Co-Diagnostics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while AMIX leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for AMIX?

Per AMIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001617867), Autonomix Medical Inc. generated $0 in revenue, -$16.7M in net income, and -$12.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is AMIX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMIX last traded at $2.04 (-5.12% on volume of 54,588 shares), positioning the stock -46.74% below its 50-day simple moving average ($3.83) and -69.96% below its 200-day simple moving average ($6.79). Across its 52-week range of $1.81 to $32.55, AMIX sits at the 0.7% percentile with a 14-day RSI of 19.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.78 to $2.30).

Q: When is AMIX's next earnings date?

Based on SEC filing cadence, Autonomix Medical Inc. (AMIX)'s next quarterly reporting window is estimated around Dec 29, 2026.

Q: How much is AMIX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for AMIX, spanning a range between $1.78 and $2.3.

$2.04 -5.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

Autonomix Medical Inc. (AMIX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $4.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.02 (-1.11%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMIX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY AMIX SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 19.7 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.11-8.4% Next Q

Q2 (-2Q)

Grade D$2.85-15.1% Next Q

Q3 (-1Q)

Grade D$2.42-15.7% Next Q

Current

Grade D-$2.04-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AMIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AMIX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.83) and Max Pain ($2.14) forces dealer call-delta covering toward $34.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMIX Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.26 Expected Swing

MODEL EARNINGS SETUP GAUGE

AMIX Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-03-31	$0	-$16.7M	-$12.3M	52%
FY 2024	2025-03-31	$0	-$11.4M	-$8.3M	52%
FY 2023	2024-03-31	$0	-$15.4M	-$6.6M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMIX)

✓Walkthrough of AMIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.43%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.08H $2.15L $1.81C $2.04VOL 134.5K

RES: $10.81SUP: $-0.07SMA50: $3.83SMA200: $6.79

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMIX Butterfly Map → + Track AMIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMIX)

Health Care Rank #768 of 1016 ⚔️ XAIR vs AMIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMIX vs. XAIR, CODX, ICCM, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Autonomix Medical Inc. (AMIX) ranks #768 by composite RQD confidence (37/100, grade D-) and #961 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while AMIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NVNO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with AMIX at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMIX ACTIVE Autonomix Medical Inc.	D-	37/100	—	—	-35.0%	-5.12%	$4.0M	Benchmark Subject
XAIR Beyond Air Inc.	D-	42/100	112.1x	3.3%	-35.0%	-2.12%	$3.8M	/xair-vs-amix →
CODX Co-Diagnostics Inc.	D-	37/100	—	64.3%	-35.0%	-10.49%	$3.5M	/codx-vs-amix →
ICCM IceCure Medical Ltd.	D	46/100	—	36.3%	-35.0%	-2.13%	$3.3M	/iccm-vs-amix →
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-amix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001617867

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Autonomix Medical Inc. (AMIX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.7M, operating cash flow of -$12.3M, and free cash flow of -$12.3M (-48.6% YoY). On the balance sheet, AMIX closed FY2025 with $10.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$0	-$16.7M	-$12.3M	-$12.3M	$10.2M	—
FY2024 (FY)	2025-03-31	$0	-$11.4M	-$8.3M	-$8.3M	$12.0M	—
FY2023 (FY)	2024-03-31	$0	-$15.4M	-$6.6M	-$6.6M	—	—

3. AMIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Autonomix Medical Inc. (NASDAQ: AMIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.04 (-5.12% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AMIX ranks #768 in composite RQD confidence.

How does AMIX compare to XAIR and CODX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AMIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XAIR (Beyond Air Inc.) holds a D- grade (42/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M) and CODX (Co-Diagnostics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while AMIX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMIX?

Per AMIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001617867), Autonomix Medical Inc. generated $0 in revenue, -$16.7M in net income, and -$12.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMIX trading relative to its 50-day, 200-day, and 52-week technical levels?

AMIX last traded at $2.04 (-5.12% on volume of 54,588 shares), positioning the stock -46.74% below its 50-day simple moving average ($3.83) and -69.96% below its 200-day simple moving average ($6.79). Across its 52-week range of $1.81 to $32.55, AMIX sits at the 0.7% percentile with a 14-day RSI of 19.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.78 to $2.30).

AMIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is AMIX's next earnings date?

Based on SEC filing cadence, Autonomix Medical Inc. (AMIX)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is AMIX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for AMIX, spanning a range between $1.78 and $2.3.

Direct Sub-Reports: AMIX RQD Cockpit AMIX 12M Forecast AMIX Earnings & Move AMIX Dividends & DRIP AMIX Insiders & 13F AMIX Whale Options AMIX Profit Sankey AMIX News & Why